Exact Sciences reported strong Q2 2024 financial results with revenue increasing 12.4% to $699.3 million, driven by 14.9% growth in Screening revenue to $531.6 million and 6.7% growth in Precision Oncology revenue to $167.7 million. The company completed over 1 million Cologuard tests in the quarter for the first time, while operating loss narrowed significantly to $26.3 million from $76.9 million year-over-year.The company continued advancing its product pipeline, with the FDA reviewing the Cologuard Plus premarket approval application and expected to make a decision in late 2024. Exact Sciences also presented promising data from its ASCEND-2 study for multi-cancer screening at AACR and secured an exclusive license to TwinStrand's cell-free nucleic acid sequencing technology for $45 million.Cash and investments totaled $946.8 million as of June 30, 2024. The company issued $620.7 million of 1.75% convertible notes due 2031, receiving net proceeds of $259.8 million. Operating cash flow was $24.8 million for the first half of 2024, with management expressing confidence in funding current operations for at least the next twelve months.

Exact Sciences reported strong Q2 2024 financial results with revenue increasing 12.4% to $699.3 million, driven by 14.9% growth in Screening revenue to $531.6 million and 6.7% growth in Precision Oncology revenue to $167.7 million. The company completed over 1 million Cologuard tests in the quarter for the first time, while operating loss narrowed significantly to $26.3 million from $76.9 million year-over-year.The company continued advancing its product pipeline, with the FDA reviewing the Cologuard Plus premarket approval application and expected to make a decision in late 2024. Exact Sciences also presented promising data from its ASCEND-2 study for multi-cancer screening at AACR and secured an exclusive license to TwinStrand's cell-free nucleic acid sequencing technology for $45 million.Cash and investments totaled $946.8 million as of June 30, 2024. The company issued $620.7 million of 1.75% convertible notes due 2031, receiving net proceeds of $259.8 million. Operating cash flow was $24.8 million for the first half of 2024, with management expressing confidence in funding current operations for at least the next twelve months.